[PART I. FINANCIAL INFORMATION](index=6&type=section&id=PART%20I.%20FINANCIAL%20INFORMATION) [Financial Statements](index=6&type=section&id=ITEM%201.%20FINANCIAL%20STATEMENTS) The company's unaudited financial statements for Q2 2021 show increased cash and equity from a private placement, revenue growth, and a narrowed net loss due to debt restructuring and new credit facilities Condensed Consolidated Balance Sheet Highlights (in thousands) | Account | June 30, 2021 | December 31, 2020 | | :--- | :--- | :--- | | **Assets** | | | | Cash and cash equivalents | $20,312 | $2,341 | | Total current assets | $49,432 | $31,365 | | Total Assets | $59,676 | $41,466 | | **Liabilities & Equity** | | | | Total current liabilities | $12,915 | $25,649 | | Long-term debt, less issuance costs | $11,683 | $0 | | Total Liabilities | $25,792 | $26,952 | | Total Stockholders' Equity | $33,884 | $14,514 | Condensed Consolidated Statements of Operations Highlights (in thousands) | Metric | Three Months Ended June 30, 2021 | Three Months Ended June 30, 2020 | Six Months Ended June 30, 2021 | Six Months Ended June 30, 2020 | | :--- | :--- | :--- | :--- | :--- | | Total Revenue | $14,975 | $10,529 | $27,517 | $25,307 | | Gross Profit | $9,515 | $6,550 | $17,606 | $16,163 | | Loss from Operations | ($491) | ($387) | ($497) | ($1,749) | | Net Loss | ($733) | ($2,464) | ($762) | ($4,957) | | Net loss per share (Basic & Diluted) | ($0.01) | ($0.19) | ($0.01) | ($0.38) | - In February 2021, the company completed a private placement, issuing 8,888,890 shares of common stock and warrants, which resulted in net cash proceeds of approximately **$18.4 million**[31](index=31&type=chunk) - On May 6, 2021, the company entered into new credit agreements for a **$12 million** term loan and an **$8 million** revolving credit facility, using the proceeds to repay all outstanding debt under its previous credit agreement with OrbiMed[51](index=51&type=chunk)[52](index=52&type=chunk)[53](index=53&type=chunk) - In July 2021, the company settled a patent infringement claim for a one-time payment of **$550,000**, accrued as a special charge in general and administrative expenses for the second quarter[64](index=64&type=chunk) [Management's Discussion and Analysis of Financial Condition and Results of Operations](index=20&type=section&id=ITEM%202.%20MANAGEMENT%27S%20DISCUSSION%20AND%20ANALYSIS%20OF%20FINANCIAL%20CONDITION%20AND%20RESULTS%20OF%20OPERATIONS) Management discusses Q2 2021 financial performance, noting a 42.2% revenue increase, improved liquidity from a private placement and new debt, and outlines growth initiatives, projecting sufficient cash through August 2022 [Results of Operations](index=21&type=section&id=Results%20of%20Operations) Q2 2021 revenue grew 42.2% to $15.0 million, driven by pandemic recovery, with gross profit margin improving to 63.5%, while operating expenses rose due to a legal settlement, and interest expense significantly decreased Revenue Comparison (in millions) | Period | 2021 | 2020 | % Change | | :--- | :--- | :--- | :--- | | Three Months Ended June 30 | $15.0 | $10.5 | +42.2% | | Six Months Ended June 30 | $27.5 | $25.3 | +8.7% | - Gross profit as a percentage of revenue increased to **63.5%** for the three months ended June 30, 2021, from 62.2% in the prior-year period, primarily due to greater economies of scale[87](index=87&type=chunk) - General and administrative expenses for the three months ended June 30, 2021, increased by **$1.2 million**, primarily due to **$0.6 million** in legal settlement expenses and **$0.2 million** in additional stock-based compensation[88](index=88&type=chunk) - Interest expense for the six months ended June 30, 2021, was **$0.2 million**, a significant decrease from **$3.2 million** in the same period of 2020, resulting from the October 2020 debt restructuring[92](index=92&type=chunk) [Liquidity and Capital Resources](index=22&type=section&id=Liquidity%20and%20Capital%20Resources) Working capital significantly increased to $36.5 million by June 2021 due to an $18.4 million private placement and new credit facilities, with operating cash flow turning positive at $0.9 million for the first half of 2021 Working Capital Summary (in thousands) | Component | June 30, 2021 | December 31, 2020 | | :--- | :--- | :--- | | Total current assets | $49,432 | $31,365 | | Total current liabilities | $12,915 | $25,649 | | **Total working capital** | **$36,517** | **$5,716** | - Net cash provided by financing activities was **$18.2 million** for the first six months of 2021, primarily from the **$18.4 million** in net proceeds from the February 2021 private placement[95](index=95&type=chunk) - On May 6, 2021, the company entered into new credit agreements with MidCap Financial Trust, establishing a **$12.0 million** term loan and an **$8.0 million** revolving credit facility, which mature on May 1, 2026[96](index=96&type=chunk)[97](index=97&type=chunk)[98](index=98&type=chunk) - The company's key growth initiatives for 2021 are: (1) introducing new products, (2) expanding its distribution network, (3) penetrating adjacent markets, and (4) leveraging its growth platform with technology and strategic acquisitions[80](index=80&type=chunk) - The company believes its cash and cash equivalents of **$20.5 million** as of June 30, 2021, along with available credit, will be sufficient to meet anticipated cash requirements through at least August 2022[104](index=104&type=chunk) [Quantitative and Qualitative Disclosures About Market Risk](index=25&type=section&id=ITEM%203.%20QUANTITATIVE%20AND%20QUALITATIVE%20DISCLOSURES%20ABOUT%20MARKET%20RISK) As a smaller reporting company, the company is exempt from providing quantitative and qualitative disclosures about market risk - The company is a smaller reporting company and is not required to provide information regarding quantitative and qualitative disclosures about market risk[111](index=111&type=chunk) [Controls and Procedures](index=25&type=section&id=ITEM%204.%20CONTROLS%20AND%20PROCEDURES) Management concluded that disclosure controls and procedures were effective as of June 30, 2021, with no material changes to internal control over financial reporting during Q2 2021 - Based on an evaluation as of June 30, 2021, the principal executive officer and principal financial officer concluded that the company's disclosure controls and procedures were effective[113](index=113&type=chunk) - No changes occurred in the company's internal control over financial reporting during the quarter ended June 30, 2021, that have materially affected, or are reasonably likely to materially affect, internal controls[114](index=114&type=chunk) [PART II. OTHER INFORMATION](index=26&type=section&id=PART%20II.%20OTHER%20INFORMATION) [Legal Proceedings](index=26&type=section&id=ITEM%201.%20LEGAL%20PROCEEDINGS) The company faces various legal claims in the ordinary course of business, with details on a recent settlement available in Note 11 of the financial statements - The company is subject to potential liabilities from various claims and legal actions that arise in the ordinary course of business; for details on pending legal proceedings, refer to Note 11 in the condensed consolidated financial statements[115](index=115&type=chunk) [Risk Factors](index=26&type=page&id=ITEM%201A.%20RISK%20FACTORS) As a smaller reporting company, the company is not required to provide risk factor disclosures in its Form 10-Q - The company is a smaller reporting company and is not required to provide information regarding risk factors in its Form 10-Q[116](index=116&type=chunk) [Unregistered Sales of Equity Securities and Use of Proceeds](index=26&type=section&id=ITEM%202.%20UNREGISTERED%20SALES%20OF%20EQUITY%20SECURITIES%20AND%20USE%20OF%20PROCEEDS) This section is not applicable for the current reporting period [Exhibits](index=26&type=section&id=ITEM%206.%20EXHIBITS) This section lists exhibits filed with the Form 10-Q, including corporate governance documents, credit agreements, and CEO/CFO certifications

Xtant Medical Holdings, Inc. (NYSE:XTNT) Q1 2021 Earnings Conference Call May 11, 2021 9:00 AM ET Company Participants Matt Steinberg - Lazar FINN Partners Sean Browne - President and CEO Greg Jensen - VP, Finance and CFO Conference Call Participants Operator Greetings, and welcome to the Xtant Medical First Quarter 2021 Financial Results Conference Call. All participants are in a listen-only mode for today's presentation. [Operator Instructions] As a reminder, this conference call is being recorded. I'd no ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 or [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ Commission File Number: 001-34951 XTANT MEDICAL HOLDINGS, INC. (Exact name of registrant as specified in its charter) | Delawar ...

Xtant Medical Holdings, Inc. (NYSE:XTNT) Q4 2020 Earnings Conference Call February 24, 2020 9:00 AM ET Company Participants Matt Steinberg - Lazar FINN Partners Sean Browne - President and CEO Greg Jensen - VP Finance and CFO Conference Call Participants Operator Greetings, and welcome to the Xtant Medical Fourth Quarter and Full Year 2020 Financial Results Conference Call. At this time, all participants are in a listen-only mode. [Operator Instructions] As a reminder, this conference is being recorded. I'd ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 or [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission file number: 001-34951 Xtant Medical Holdings, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 20-531332 ...

Xtant Medical Holdings, Inc. (NYSE:XTNT) Q3 2020 Earnings Conference Call October 29, 2020 9:00 AM ET Company Participants David Carey - Lazar FINN Partners Sean Browne - President and CEO Greg Jensen - VP, Finance and CFO Conference Call Participants Operator Greetings, and welcome to the Xtant Medical's Q3 2020 Financial Results. At this time, all participants are in a listen-only mode. [Operator Instructions] As a reminder, this conference is being recorded. I would now like to turn the conference over t ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 or [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (Exact name of registrant as specified in its charter) | Delaware | 20-5313323 | | --- | --- | | (State or other jurisdiction of | (I.R.S. Employer | | incorporation or organization ...

Xtant Medical Holdings, Inc. (NYSE:XTNT) Q2 2020 Results Earnings Conference Call August 3, 2020 4:30 PM ET Company Participants Matt Steinberg - Investor Relations, Associate Vice President at Lazar FINN Partners Sean Browne - President, Chief Executive Officer Greg Jensen - Vice President of Finance, Chief Financial Officer Conference Call Participants Operator Greetings and welcome to Xtant Medical second quarter 2020 financial results conference call. At this time, all participants are in a listen-only ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 or [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ Commission File Number: 001-34951 XTANT MEDICAL HOLDINGS, INC. (Exact name of registrant as specified in its charter) | Delaware ...

Financial Data and Key Metrics Changes - Total revenue for Q1 2020 was $14.8 million, down from $16.7 million in Q1 2019, primarily due to the impact of COVID-19 and the halt of elective procedures [21] - Gross margin for Q1 2020 was 65.0%, slightly up from 64.6% in the same period a year ago [22] - Net loss for Q1 2020 was $2.5 million or $0.19 per share, compared to a net loss of $2.8 million or $0.21 per share in Q1 2019 [25] Business Line Data and Key Metrics Changes - General and administrative expenses decreased to $4.3 million in Q1 2020 from $4.5 million in Q1 2019, mainly due to lower legal expenses and consulting fees [23] - Sales and marketing expenses were $6.4 million for Q1 2020, down 5% from $6.7 million in Q1 2019, attributed to lower sales commissions due to decreased sales [24] - Research and development expenses were approximately $250,000 for Q1 2020, slightly down from $262,000 in Q1 2019 [25] Market Data and Key Metrics Changes - As of March 31, 2020, the company had $3.2 million in cash and cash equivalents, $9.7 million in net accounts receivable, and $18 million in inventory [26] Company Strategy and Development Direction - The company identified four areas for improvement to emerge stronger from the COVID-19 crisis, including employee safety, cost reduction initiatives, addressing production shortfalls, and optimizing customer management [12][14][16][17] - The company aims to operate as a leaner organization and improve the efficiency of biologics production to fulfill its mission as conditions normalize [19] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the resumption of elective procedures and the progress made in transforming the organization before the pandemic [18] - The company believes that cost-saving actions in response to the pandemic will help navigate through the current uncertainty [28] Other Important Information - The company has enacted workforce reductions and furloughs, along with pay decreases for all employees and the Board of Directors as part of its cost-saving measures [14] Q&A Session Summary - The Q&A session concluded without any recorded questions or answers, indicating a lack of engagement from participants during this segment [30]